Press & Events
AVEO Oncology to Present at the 31st Annual J.P. Morgan Healthcare Conference
AVEO awaits final blessing on cancer drug
Source: The Boston GlobeAVEO Oncology Appoints Robert Epstein, M.D., M.S. to its Board of Directors
AVEO and Astellas Announce Initiation of Patient Enrollment in Phase 2 Trial of Tivozanib in Combination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer
FDA accepts Aveo kidney cancer pill application
Source: BloombergBusinessweekAVEO Pharmaceuticals' Tivozanib Clinical Data Featured at 2011 ASCO Gastrointestinal Cancers Symposium
AVEO Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating SCH 900105 (AV-299) in Non-Small Cell Lung Cancer
AVEO Pharmaceuticals to Present at the Bank of America Merrill Lynch 2010 Smid Cap Conference
AVEO Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
AVEO Pharmaceuticals Files Registration Statement for Initial Public Offering
Archived Press
2013
AprilMarch
February
January
2012
DecemberNovember
October
September
August
July
June
May
April
March
February
January